Tesaro (TSRO) PT Raised to $128 at RBC Capital

RBC Capital analyst Adnan Butt reiterated an Outperform rating and raised its price target on Tesaro (NASDAQ: TSRO) to $128.00 (from $122.00) following NOVA Phase 3 trial details.

Butt commented, "Details show biomarker/HRD-positive benefit is not driven by somatic BRCA patients alone, biomarker/HRD-negative population shows a stat sig benefit, which allows TSRO to file broadly for platinum sensitive ovarian cancer patients, the broadest addressable market and an upside scenario, and safety/tolerability differences could point to further PARP inhibitor separation. Niraparib is the PARP inhibitor to beat and there is no legitimate competitive threat near-term. PT to $128 from $122."

For an analyst ratings summary and ratings history on Tesaro click here. For more ratings news on Tesaro click here.

Shares of Tesaro closed at $99.26 yesterday.

You May Also Be Interested In

• Nurix (NRIX) PT Raised to $36 at H.C. Wainwright
• Strategy (MSTR) PT Raised to $208 at Cantor Fitzgerald to Reflect Recent BTC Holdings, USD Reserves
• Macquarie Upgrades Pigeon Corp (7956:JP) to Outperform